METASTATIC PANCREATIC ADENOCARCINOMA

This trial tested a new treatment called EGFR BATs for people with advanced pancreatic cancer. The treatment uses a patient's own immune cells, armed with a special antibody, to target cancer cells. The study included 22 participants who had already received chemotherapy. The goa…

This early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…

This phase 2 trial tested whether adding the drug veliparib to standard chemotherapy (FOLFIRI) helps people with metastatic pancreatic cancer live longer. 123 patients whose cancer had returned after initial treatment were randomly assigned to get FOLFIRI alone or FOLFIRI plus ve…

This study tested whether adding two experimental drugs (TTX-030 and budigalimab) to standard chemotherapy could help people with metastatic pancreatic cancer live longer without their disease getting worse. 194 adults who had not yet received treatment for their advanced cancer …

This study tested a combination of four drugs (tadalafil, pembrolizumab, ipilimumab, and CRS-207) in 17 people with advanced pancreatic cancer that had worsened after at least one round of chemotherapy. The goal was to see if the combination was safe and could shrink tumors. The …

This study tested a combination of two oral drugs, ribociclib and everolimus, in 12 people with metastatic pancreatic cancer that had stopped responding to standard chemotherapy. The goal was to find the right dose and see if it could slow tumor growth. The trial was small and ea…

This early-phase trial tested two drugs—binimetinib and hydroxychloroquine—in 34 people with a specific type of advanced pancreatic cancer (KRAS-mutant) that had spread. The goal was to find the safest dose of hydroxychloroquine when used with binimetinib, and to see if the combi…

This study tested an experimental immunotherapy called indoximod added to standard chemotherapy (gemcitabine and nab-paclitaxel) in 157 people with metastatic pancreatic cancer. The goal was to find a safe dose and see if the combination helps people live longer. The trial has co…

This early-phase trial tested an experimental oral drug called IOA-289 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in 16 people with metastatic pancreatic cancer. The main goal was to check safety and find the right dose. Researchers also looked at how th…

This phase 2 study tested a combination of three drugs—gemcitabine, trastuzumab, and erlotinib—as a first treatment for people with metastatic pancreatic cancer that has spread. The goal was to see if the combination could control tumor growth. 63 patients received the drugs intr…

This phase II trial tested whether adding paricalcitol (a vitamin D drug) and hydroxychloroquine (an autophagy inhibitor) to standard chemotherapy could help shrink tumors in 10 people with advanced or metastatic pancreatic cancer. The goal was to see if the combination improved …

This study looked at 211 people with advanced pancreatic cancer whose first treatment (FOLFIRINOX) stopped working or caused too many side effects. Researchers compared a two-drug combination (gemcitabine and paclitaxel) against gemcitabine alone to see if the combo helped people…

This early-phase trial tested a new way to treat advanced cancers that have spread. It combined a special type of radiation with two immunotherapy drugs (MEDI4736 and tremelimumab) to see if the combination is safe and tolerable. The study included 53 adults with advanced melanom…

This phase 2 trial tested two drugs, cabozantinib and pembrolizumab, in 21 people with metastatic pancreatic cancer that had worsened after standard treatment. The goal was to see if the combination could slow cancer growth. The study is complete, and results may help guide futur…

This study tested a new combination of drugs (ABT-888 plus chemotherapy) in 64 people with pancreatic cancer that had spread. The goal was to see if adding ABT-888, which blocks cancer cells from fixing DNA damage, could make chemotherapy work better and shrink tumors. The study …

This early-phase trial tested different combinations of immunotherapy drugs with standard chemotherapy for people with metastatic pancreatic cancer that had not been treated before. The main goal was to check safety and see if the combinations could shrink tumors or control the d…

This early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …

This study tested a drug called telotristat ethyl in 23 people with advanced pancreatic cancer who had lost at least 10% of their body weight. The goal was to see if the drug could help them stabilize or gain weight by reducing bowel movements. Maintaining weight may help patient…